Fig. 1From: Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in IsraelDistribution of the maximum WTP for the hypothetical mRNA treatment. A Entire sample, B Survival probability from current 20% to potential 40%, C Survival probability from current 20% to potential 60%Back to article page